EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study

Takashi Yokota, Shintaro Kinugawa, Arata Fukushima, Takahiro Okumura, Toyoaki Murohara, Hiroyuki Tsutsui, LEAF-CHF Investigators

Heart and Vessels · 2025

DOI: 10.1007/s00380-024-02448-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Heart and Vessels, 2025. Verfasst von Takashi Yokota und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. t-yokota@med.hokudai…. Hauptthemen laut MEDLINE: Hyperuricemia, Febuxostat, Heart Failure, Uric Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Teijin Pharma Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaFebuxostatHeart FailureUric AcidGout SuppressantsHumansMaleFemaleAgedProspective StudiesTreatment OutcomeMiddle AgedNatriuretic Peptide, BrainVentricular Function, LeftJapanStroke VolumeBiomarkersChronic DiseaseTime Factors

Stichwörter der Autor:innen

B-type natriuretic peptideChronic heart failureClinical trialOxidative stressXanthine oxidase inhibitor

Substanzen

FebuxostatUric AcidNatriuretic Peptide, BrainGout SuppressantsBiomarkers

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. t-yokota@med.hokudai.ac.jp.
  • Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Kita-14 Nishi-5, Kita-ku, Sapporo, 060-8648, Japan. t-yokota@med.hokudai.ac.jp.
  • Department Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Division of Cardiovascular Medicine, Faculty of Medical Sciences, Research Institute of Angiocardiology, Kyushu University, Fukuoka, Japan.
  • Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Förderung

  • Teijin Pharma Ltd

Zitieren

APA

Yokota, T., Kinugawa, S., Fukushima, A., Okumura, T., Murohara, T., Tsutsui, H., & LEAF-CHF Investigators (2025). Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study. Heart and Vessels. https://doi.org/10.1007/s00380-024-02448-9

Vancouver

Yokota T, Kinugawa S, Fukushima A, Okumura T, Murohara T, Tsutsui H, et al. Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study. Heart and Vessels. 2025. doi:10.1007/s00380-024-02448-9

BibTeX
@article{Yokota2025,
  author = {Yokota, Takashi and Kinugawa, Shintaro and Fukushima, Arata and Okumura, Takahiro and Murohara, Toyoaki and Tsutsui, Hiroyuki and LEAF-CHF Investigators, LEAF-CHF Investigators},
  title = {Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study},
  journal = {Heart and Vessels},
  year = {2025},
  doi = {10.1007/s00380-024-02448-9}
}
Kostenlos starten →